Volition Announces Cameron Reynolds, President and Chief Executive Officer Invited as Presenter at Maxim's COVID-19 Virtual Conference
May 22, 20209:15 PM
VolitionRx Announces Closing of $13.8 Million Public Offering of Common Stock
May 20, 20202:00 PM
VolitionRx Announces Pricing of Underwritten Public Offering of Common Stock
May 13, 202010:15 PM
VolitionRx To Present First Data on Nu.Q™ Capture Performance and Nu.Q™ Assay Performance in Lung Cancer and Blood Cancer at the 2020 ASCO Annual Meeting
May 07, 20209:15 PM
VolitionRx Limited Announces First Quarter 2020 Financial Results and Business Update
May 05, 20201:45 PM
VolitionRx Limited Schedules First Quarter 2020 Earnings Conference Call and Business Update
Apr 29, 20201:45 PM
Volition's Nu.Q™ Vet Assay Detects Two Common Canine Cancers
Apr 23, 20201:45 PM
Volition Files Patent for Nu.Q(TM) COVID-19 Triage Test and Commences Proof of Concept Studies
Mar 10, 20201:00 PM
VolitionRx Limited Releases Annual Corporate Brochure and Video
Mar 03, 20201:45 PM
VolitionRx Limited to Present at Conferences in March 2020
Feb 20, 20209:15 PM
VolitionRx Limited Announces Full Fiscal Year 2019 Financial Results and Business Update
Feb 18, 20209:15 PM
VolitionRx Limited Schedules Full Year 2019 Earnings Conference Call and Business Update
Feb 18, 20201:45 PM
Volition Unveils Its Epigenetic Toolbox
Feb 07, 202010:45 PM
VolitionRx Announces Filing of Registration Statements
Jan 13, 20202:15 PM
Volition Develops a New Improved Nu.Q™ Assay Format